← 홈

Antibody · 혈액암 (AML/ALL)

212개 · ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-8 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 212개
AntibodyHotRochePhase 3

atezolizumab (Tecentriq)

Advanced Solid Tumor · Thoracic Neoplasms, Lung Diseases, Small

#ThoracicNeoplasmsLungDiseasesSma#Antibody#Phase3#인기#항체+5
효능 ORR 95%임상시험 655상태 RECRUITING
AntibodyAHotRocheApproved

Tocilizumab (Tocilizumab)

Multiple Myeloma (MM); Multiple Myeloma Refractory · Chronic Lymphocytic Leukemia

#ChronicLymphocyticLeukemia#Antibody#Approved#인기#항체+5
효능 ORR 95%임상시험 141상태 RECRUITING
AntibodyCHotBeiGeneVedotin, Tislelizumab, and …Phase 2

Tislelizumab (Tislelizumab)

Locally Recurrent Colorectal Cancer · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase2#인기#항체+5
효능 ORR 37.1%임상시험 125상태 RECRUITING
AntibodyAHotMerck KGaAvedotin (EV) was the most c…Phase 3

Avelumab (Avelumab)

Non Small Cell Lung Cancer; Colorectal Cancer · Locally Advanced or Metastatic Urothelia

#LocallyAdvancedorMetastaticUroth#Antibody#Phase3#인기#항체+5
효능 ORR 74%임상시험 123상태 ACTIVE
AntibodyCHotstaleXin-Hua XuPhase 2

AK104 (Cadonilimab, Cadonilimab (AK104))

Non-small Cell Lung Cancer · Leptomeningeal Metastasis

#LeptomeningealMetastasis#Antibody#Phase2#인기#항체+5
임상시험 101상태 RECRUITING
AntibodyAstaleRochePhase 3

atezolizumab (Tecentriq, MPDL3280A, Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody)

Carcinoma, Non-Squamous Non-Small Cell Lung · PD-L1

#PD-L1#Antibody#Phase3#인기#항체+5
효능 ORR 76.7%임상시험 88상태 ACTIVE
AntibodyBstaleEli Lilly and CompanyDeruxtecan]Phase 3

Ramucirumab (Ramucirumab)

Advanced Esophageal Adenocarcinoma; Advanced Gastric Adenocarcinoma · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase3#인기#항체+5
효능 ORR 40%임상시험 86상태 RECRUITING
AntibodyAstaleRocheGovitecanPhase 3

carboplatin-etoposide (Atezolizumab + chemotherapy, Atezolizumab + chemotherapy (carboplatin-etoposide))

Extensive Stage Small Cell Lung Cancer · Extensive Stage Small Cell Lung Cancer

#ExtensiveStageSmallCellLungCance#Antibody#Phase3#인기#항체+5
효능 ORR 100%임상시험 83상태 RECRUITING
AntibodyBstaleAmgenPhase 3

Blinatumomab (Blinatumomab)

B Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 · Precursor Cell Lymphoblastic Leukemia-Ly

#PrecursorCellLymphoblasticLeukem#Antibody#Phase3#인기#항체+5
효능 ORR 11.1%임상시험 83상태 RECRUITING
AntibodyCstaleMiltenyi Biomedicine GmbHPhase 3

Alemtuzumab (Alemtuzumab)

Leukemia; Lymphoma · Fanconi Anemia

#FanconiAnemia#Antibody#Phase3#인기#항체+5
효능 ORR 33%임상시험 71상태 DISCONTINUED
AntibodystaleRocheApproved

Omalizumab (Omalizumab)

Chronic Rhinosinusitis With Nasal Polyps (CRSwNP); Chronic Rhinosinusitis (CRS) · Persistent Allergic Asthma

#PersistentAllergicAsthma#Antibody#Approved#인기#항체+5
임상시험 67상태 ACTIVE
AntibodystaleHoffmann-La Rochevedotin plus bendamustine a…Phase 3

Glofitamab (Glofitamab)

Diffuse Large B Cell Lymphoma (DLBCL); High Grade B Cell Lymphoma · Chronic Lymphocytic Leukemia

#ChronicLymphocyticLeukemia#Antibody#Phase3#인기#항체+5
임상시험 66상태 RECRUITING
AntibodystaleAstraZenecavedotin combined with pembr…Phase 3

Durvalumab (MEDI4736, MEDI4736 (Durvalumab))

Non-Small-Cell Lung Carcinoma NSCLC · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase3#인기#항체+5
효능 ORR 36.3%임상시험 65상태 ACTIVE
AntibodystaleNovartisPhase 3

Ofatumumab (Ofatumumab)

Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma · Leukemia

#Leukemia#Antibody#Phase3#인기#항체+5
효능 ORR 78.4%임상시험 65상태 RECRUITING
AntibodystaleRochegovitecan in patients with …Preclinical

MPDL3280A (Atezolizumab, Atezolizumab (MPDL3280A))

Non-Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Preclinical#인기#항체+4
효능 ORR 46.4%임상시험 60상태 ACTIVE
AntibodystaleJanssenApproved

Teclistamab (Teclistamab)

Myeloma Multiple; Plasma Cell Leukemia · Myeloma Multiple

#MyelomaMultiple#Antibody#Approved#인기#항체+5
임상시험 60상태 RECRUITING
AntibodystaleBristol Myers SquibbPhase 2

nivolumab (Opdivo, ipilimumab + nivolumab)

Solid Tumor; Non Small Cell Lung Cancer · Solid Tumor

#SolidTumor#Antibody#Phase2#인기#항체+4
효능 ORR 77.8%임상시험 60상태 RECRUITING
AntibodystaleRegeneronDemonstratePhase 2

Cemiplimab + Fianlimab [Fixed Dose Combination (FDC, Cemiplimab + Fianlimab [Fixed Dose Combination, Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)])

Ovarian Cancer; Fallopian Tube Cancer · Ovarian Cancer

#OvarianCancer#Antibody#Phase2#인기#항체+5
효능 ORR 100%임상시험 59상태 RECRUITING
AntibodystaleWei-Che KoPhase 3

Canakinumab (Canakinumab)

Skin Inflammation; Allergic Contact Dermatitis · Skin Inflammation

#SkinInflammation#Antibody#Phase3#인기#항체+5
효능 ORR 4.9%임상시험 57상태 RECRUITING
AntibodystaleAstraZenecavedotin combined with pembr…Phase 3

durvalumab (Imfinzi, MEDI4736, MEDI4736 (Durvalumab) + Tremelimumab)

Non-Small-Cell Lung Carcinoma NSCLC · Advanced Solid Malignancies

#AdvancedSolidMalignancies#Antibody#Phase3#인기#항체+5
효능 ORR 100%임상시험 56상태 RECRUITING

1 / 11 페이지

← 이전다음 →